Logo image of PTIX

PROTAGENIC THERAPEUTICS INC (PTIX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PTIX - US74365N3017 - Common Stock

0.74 USD
-0.56 (-43.08%)
Last: 1/2/2026, 8:00:01 PM
0.43 USD
-0.31 (-41.89%)
After Hours: 1/2/2026, 8:00:01 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to PTIX. PTIX was compared to 530 industry peers in the Biotechnology industry. PTIX has a bad profitability rating. Also its financial health evaluation is rather negative. PTIX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PTIX has reported negative net income.
PTIX had a negative operating cash flow in the past year.
In the past 5 years PTIX always reported negative net income.
In the past 5 years PTIX always reported negative operating cash flow.
PTIX Yearly Net Income VS EBIT VS OCF VS FCFPTIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1M -2M -3M -4M -5M

1.2 Ratios

With a Return On Assets value of -178.31%, PTIX is not doing good in the industry: 86.98% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -178.31%
ROE N/A
ROIC N/A
ROA(3y)-147.64%
ROA(5y)-153.54%
ROE(3y)-244.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTIX Yearly ROA, ROE, ROICPTIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PTIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTIX Yearly Profit, Operating, Gross MarginsPTIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, PTIX has more shares outstanding
PTIX has more shares outstanding than it did 5 years ago.
PTIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PTIX Yearly Shares OutstandingPTIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100K 200K 300K 400K 500K
PTIX Yearly Total Debt VS Total AssetsPTIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -9.04, we must say that PTIX is in the distress zone and has some risk of bankruptcy.
PTIX's Altman-Z score of -9.04 is on the low side compared to the rest of the industry. PTIX is outperformed by 70.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.04
ROIC/WACCN/A
WACCN/A
PTIX Yearly LT Debt VS Equity VS FCFPTIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M

2.3 Liquidity

A Current Ratio of 0.29 indicates that PTIX may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.29, PTIX is doing worse than 92.08% of the companies in the same industry.
PTIX has a Quick Ratio of 0.29. This is a bad value and indicates that PTIX is not financially healthy enough and could expect problems in meeting its short term obligations.
PTIX's Quick ratio of 0.29 is on the low side compared to the rest of the industry. PTIX is outperformed by 91.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
PTIX Yearly Current Assets VS Current LiabilitesPTIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 54.53% over the past year.
EPS 1Y (TTM)54.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTIX Yearly EPS VS EstimatesPTIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTIX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTIX Price Earnings VS Forward Price EarningsPTIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTIX Per share dataPTIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTIX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PROTAGENIC THERAPEUTICS INC

NASDAQ:PTIX (1/2/2026, 8:00:01 PM)

After market: 0.43 -0.31 (-41.89%)

0.74

-0.56 (-43.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14
Earnings (Next)03-30 2026-03-30
Inst Owners6.08%
Inst Owner Change0%
Ins Owners2.86%
Ins Owner Change0%
Market Cap1.43M
Revenue(TTM)N/A
Net Income(TTM)-8.92M
Analysts82.86
Price TargetN/A
Short Float %3.35%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0
BVpS-2.44
TBVpS-3.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -178.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-147.64%
ROA(5y)-153.54%
ROE(3y)-244.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z -9.04
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.26%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.09%
OCF growth 3YN/A
OCF growth 5YN/A

PROTAGENIC THERAPEUTICS INC / PTIX FAQ

What is the ChartMill fundamental rating of PROTAGENIC THERAPEUTICS INC (PTIX) stock?

ChartMill assigns a fundamental rating of 0 / 10 to PTIX.


Can you provide the valuation status for PROTAGENIC THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to PROTAGENIC THERAPEUTICS INC (PTIX). This can be considered as Overvalued.


What is the profitability of PTIX stock?

PROTAGENIC THERAPEUTICS INC (PTIX) has a profitability rating of 0 / 10.


How financially healthy is PROTAGENIC THERAPEUTICS INC?

The financial health rating of PROTAGENIC THERAPEUTICS INC (PTIX) is 0 / 10.